Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer

Morag Catherine Elliott McFadyen, Margaret Eleanor Cruickshank, Iain D Miller, H. L. McLeod, William Thomas Melvin, Neva Elizabeth Haites, David Parkin, Graeme Ian Murray

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Ovarian cancer is the most frequent cause of death from gynaecological malignancies world wide. Little improvement has been made in the long-term outcome of this disease, with the 5-year survival of patients only 30%. This poor prognosis is due to the late presentation of the disease and to the unpredictable response of ovarian cancer to chemotherapy. The cytochrome P450 enzymes are a superfamily of haemoproteins, known to be involved in the metabolic activation and/or detoxification of a number of anti-cancer drugs. CYP1B1 is a tumour-related form of cytochrome P450 which is over expressed in a wide variety of primary tumours of different histological type. The presence of CYP1B1 may be of importance in the modulation of these tumours to anti-cancer drugs. We have conducted a comprehensive immunohistochemical investigation, into the presence of cytochrome P450 CY1B1 in primary and metastatic ovarian cancer. The key findings of this study are the increased expression of CYP1B1 in the majority of ovarian cancers investigated (92%). with a strong correlation demonstrated between CYP1B1 expression in both primary and metastatic ovarian cancer (P = 0.005 Spearman's rank correlation test). In contrast no detectable CYP1B1 was found in normal ovary. (C) 2001 Cancer Research Campaign.

Original languageEnglish
Pages (from-to)242-246
Number of pages4
JournalBritish Journal of Cancer
Volume85
Issue number2
DOIs
Publication statusPublished - 2001

Keywords

  • cytochrome P450
  • docetaxel
  • anti-cancer drug
  • CARCINOMA
  • ENZYMES
  • CYP1B1
  • P450

Cite this

Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. / McFadyen, Morag Catherine Elliott; Cruickshank, Margaret Eleanor; Miller, Iain D; McLeod, H. L.; Melvin, William Thomas; Haites, Neva Elizabeth; Parkin, David; Murray, Graeme Ian.

In: British Journal of Cancer, Vol. 85, No. 2, 2001, p. 242-246.

Research output: Contribution to journalArticle

McFadyen, Morag Catherine Elliott ; Cruickshank, Margaret Eleanor ; Miller, Iain D ; McLeod, H. L. ; Melvin, William Thomas ; Haites, Neva Elizabeth ; Parkin, David ; Murray, Graeme Ian. / Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. In: British Journal of Cancer. 2001 ; Vol. 85, No. 2. pp. 242-246.
@article{8d460aeb8e1848a2af4aea17d8a13f0b,
title = "Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer",
abstract = "Ovarian cancer is the most frequent cause of death from gynaecological malignancies world wide. Little improvement has been made in the long-term outcome of this disease, with the 5-year survival of patients only 30{\%}. This poor prognosis is due to the late presentation of the disease and to the unpredictable response of ovarian cancer to chemotherapy. The cytochrome P450 enzymes are a superfamily of haemoproteins, known to be involved in the metabolic activation and/or detoxification of a number of anti-cancer drugs. CYP1B1 is a tumour-related form of cytochrome P450 which is over expressed in a wide variety of primary tumours of different histological type. The presence of CYP1B1 may be of importance in the modulation of these tumours to anti-cancer drugs. We have conducted a comprehensive immunohistochemical investigation, into the presence of cytochrome P450 CY1B1 in primary and metastatic ovarian cancer. The key findings of this study are the increased expression of CYP1B1 in the majority of ovarian cancers investigated (92{\%}). with a strong correlation demonstrated between CYP1B1 expression in both primary and metastatic ovarian cancer (P = 0.005 Spearman's rank correlation test). In contrast no detectable CYP1B1 was found in normal ovary. (C) 2001 Cancer Research Campaign.",
keywords = "cytochrome P450, docetaxel, anti-cancer drug, CARCINOMA, ENZYMES, CYP1B1, P450",
author = "McFadyen, {Morag Catherine Elliott} and Cruickshank, {Margaret Eleanor} and Miller, {Iain D} and McLeod, {H. L.} and Melvin, {William Thomas} and Haites, {Neva Elizabeth} and David Parkin and Murray, {Graeme Ian}",
year = "2001",
doi = "10.1054/bjoc.2001.1907",
language = "English",
volume = "85",
pages = "242--246",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer

AU - McFadyen, Morag Catherine Elliott

AU - Cruickshank, Margaret Eleanor

AU - Miller, Iain D

AU - McLeod, H. L.

AU - Melvin, William Thomas

AU - Haites, Neva Elizabeth

AU - Parkin, David

AU - Murray, Graeme Ian

PY - 2001

Y1 - 2001

N2 - Ovarian cancer is the most frequent cause of death from gynaecological malignancies world wide. Little improvement has been made in the long-term outcome of this disease, with the 5-year survival of patients only 30%. This poor prognosis is due to the late presentation of the disease and to the unpredictable response of ovarian cancer to chemotherapy. The cytochrome P450 enzymes are a superfamily of haemoproteins, known to be involved in the metabolic activation and/or detoxification of a number of anti-cancer drugs. CYP1B1 is a tumour-related form of cytochrome P450 which is over expressed in a wide variety of primary tumours of different histological type. The presence of CYP1B1 may be of importance in the modulation of these tumours to anti-cancer drugs. We have conducted a comprehensive immunohistochemical investigation, into the presence of cytochrome P450 CY1B1 in primary and metastatic ovarian cancer. The key findings of this study are the increased expression of CYP1B1 in the majority of ovarian cancers investigated (92%). with a strong correlation demonstrated between CYP1B1 expression in both primary and metastatic ovarian cancer (P = 0.005 Spearman's rank correlation test). In contrast no detectable CYP1B1 was found in normal ovary. (C) 2001 Cancer Research Campaign.

AB - Ovarian cancer is the most frequent cause of death from gynaecological malignancies world wide. Little improvement has been made in the long-term outcome of this disease, with the 5-year survival of patients only 30%. This poor prognosis is due to the late presentation of the disease and to the unpredictable response of ovarian cancer to chemotherapy. The cytochrome P450 enzymes are a superfamily of haemoproteins, known to be involved in the metabolic activation and/or detoxification of a number of anti-cancer drugs. CYP1B1 is a tumour-related form of cytochrome P450 which is over expressed in a wide variety of primary tumours of different histological type. The presence of CYP1B1 may be of importance in the modulation of these tumours to anti-cancer drugs. We have conducted a comprehensive immunohistochemical investigation, into the presence of cytochrome P450 CY1B1 in primary and metastatic ovarian cancer. The key findings of this study are the increased expression of CYP1B1 in the majority of ovarian cancers investigated (92%). with a strong correlation demonstrated between CYP1B1 expression in both primary and metastatic ovarian cancer (P = 0.005 Spearman's rank correlation test). In contrast no detectable CYP1B1 was found in normal ovary. (C) 2001 Cancer Research Campaign.

KW - cytochrome P450

KW - docetaxel

KW - anti-cancer drug

KW - CARCINOMA

KW - ENZYMES

KW - CYP1B1

KW - P450

U2 - 10.1054/bjoc.2001.1907

DO - 10.1054/bjoc.2001.1907

M3 - Article

VL - 85

SP - 242

EP - 246

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -